ARS Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ARS Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2023.
  • ARS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$19.1M, a 28.7% decline year-over-year.
  • ARS Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$49.1M, a 20.3% increase year-over-year.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$54.4M, a 56.8% decline from 2022.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$34.7M, a 71.3% decline from 2021.
  • ARS Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$20.2M, a 38.6% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$54.4M -$19.7M -56.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$34.7M -$14.4M -71.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$20.2M +$12.7M +38.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$32.9M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.